Back to Search Start Over

A pulmonary rehabilitation program reduces hospitalizations in chronic obstructive pulmonary disease patients: A cost-effectiveness study.

Authors :
Toubes-Navarro, Maria
Gude-Sampedro, Francisco
Álvarez-Dobaño, José
Reyes-Santias, Francisco
Rábade-Castedo, Carlos
Rodríguez-García, Carlota
Lado-Baleato, Óscar
Lago-Fidalgo, Raquel
Sánchez-Martínez, Noelia
Ricoy-Gabaldón, Jorge
Casal-Mouriño, Ana
Abelleira-Paris, Romina
Riveiro-Blanco, Vanessa
Zamarrón-Sanz, Carlos
Rodríguez-Núñez, Nuria
Lama-López, Adriana
Ferreiro-Fernández, Lucía
Valdés-Cuadrado, Luis
Source :
Annals of Thoracic Medicine. Oct-Dec2023, Vol. 18 Issue 4, p190-198. 9p.
Publication Year :
2023

Abstract

BACKGROUND: Although pulmonary rehabilitation (PR) is recommended in patients with chronic obstructive pulmonary disease (COPD), there is a scarcity of data demonstrating the cost-effectiveness and effectiveness of PR in reducing exacerbations. METHODS: A quasi-experimental study in 200 patients with COPD was conducted to determine the number of exacerbations 1 year before and after their participation in a PR program. Quality of life was measured using the COPD assessment test and EuroQol-5D. The costs of the program and exacerbations were assessed the year before and after participation in the PR program. The incremental cost-effectiveness ratio (ICER) was estimated in terms of quality-adjusted life years (QALYs). RESULTS: The number of admissions, length of hospital stay, and admissions to the emergency department decreased after participation in the PR program by 48.2%, 46.6%, and 42.5%, respectively (P < 0.001 for all). Results on quality of life tests improved significantly (P < 0.001 for the two tests). The cost of PR per patient and the cost of pre-PR and post-PR exacerbations were €1867.7 and €7895.2 and €4201.9, respectively. The PR resulted in a cost saving of €1826 (total, €365,200) per patient/year, and the gain in QALYs was+0.107. ICER was −€17,056. The total cost was <€20,000/QALY in 78% of patients. Conclusions: PR contributes to reducing the number of exacerbations in patients with COPD, thereby slowing clinical deterioration. In addition, it is cost-effective in terms of QALYs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
18171737
Volume :
18
Issue :
4
Database :
Academic Search Index
Journal :
Annals of Thoracic Medicine
Publication Type :
Academic Journal
Accession number :
173997587
Full Text :
https://doi.org/10.4103/atm.atm_70_23